GoodRx(US:GDRX)2025-11-04 21:23Revenue Performance - Revenue for Q3 2025 increased to $196.0 million, slightly up from $195.3 million in the same period last year[3] - Total revenue for the three months ended September 30, 2025, was $196.028 million, a slight increase of 0.4% compared to $195.251 million in the same period of 2024[29] - For FY 2025, the company anticipates revenue growth from $792.3 million in FY 2024, with adjusted EBITDA guidance of $265 - $275 million[12] Consumer Metrics - The company exited Q3 2025 with over 6 million prescription-related consumers using GoodRx services[23] - Monthly Active Consumers decreased to 5.4 million in September 2025 from 6.6 million in September 2024, representing a decline of approximately 18.2% year-over-year[24] - Subscription plans decreased to 671,000 in September 2025 from 701,000 in September 2024, reflecting a decline of approximately 4.3% year-over-year[24] Income and Profitability - Net income for Q3 2025 was $1.1 million, with a net income margin of 0.6%, down from $4.0 million and 2.0% respectively[6] - Operating income for the three months ended September 30, 2025, was $14.620 million, down 28.0% from $20.407 million in the same period of 2024[29] - Net income for the nine months ended September 30, 2025, was $25.014 million, compared to $9.650 million in the same period of 2024, indicating a significant increase of 159.4%[31] Cash Flow and Liquidity - Cash flow from operating activities was $76.0 million, down from $86.9 million in the same quarter last year[8] - Cash and cash equivalents decreased to $273.529 million as of September 30, 2025, down from $448.346 million at the end of December 2024, a decline of 39.0%[26] Expenses and Cost Management - Sales and marketing expenses for Q3 2025 were $83,532 thousand, accounting for 43% of revenue, down from 46% in Q3 2024[46] - General and administrative expenses for Q3 2025 were $32,014,000, an increase of 25.0% from $25,619,000 in Q3 2024[50] - Stock-based compensation expense for the nine months ended September 30, 2025, was $58,707,000, down from $78,067,000 in the same period of 2024[50] Adjusted Metrics - Adjusted EBITDA for Q3 2025 was $66.3 million, with an adjusted EBITDA margin of 33.8%, compared to $65.0 million and 33.3% in the prior year[7] - Adjusted Net Income for the nine months ended September 30, 2025, was $97,087 thousand, compared to $96,894 thousand for the same period in 2024, showing a marginal increase of 0.2%[44] - Adjusted Earnings Per Share (EPS) for Q3 2025 was $0.08, consistent with Q3 2024, while the diluted EPS also remained at $0.08[44] Asset and Liability Management - Total assets decreased to $1.325 billion as of September 30, 2025, from $1.388 billion at the end of December 2024, a decrease of approximately 4.5%[26] - Total liabilities increased to $724.795 million as of September 30, 2025, compared to $663.409 million at the end of December 2024, an increase of approximately 9.2%[27] Depreciation and Amortization - The company reported a total of $62.072 million in depreciation and amortization for the nine months ended September 30, 2025, compared to $50.442 million in the same period of 2024, an increase of 23.1%[31] - Depreciation and amortization for the nine months ended September 30, 2025, was $62,072,000, an increase of 23.0% from $50,442,000 in the same period of 2024[50] Share Repurchase - The company repurchased 13.4 million shares for $61.6 million during Q3 2025, with $81.4 million remaining in its share repurchase program[11]